Coagulants Market Size, Share & Trends Analysis Report By Product (Systemic, Topical, Hemostatics), By Application (Surgeries, Trauma, Hemophilia, Bleeding), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030
Coagulants Market Size & Trends
The global coagulants market size was estimated at USD 10.47 billion in 2023 and is projected to grow at a CAGR of 7.2% from 2024 to 2030. The market in healthcare is primarily driven by the increasing prevalence of bleeding disorders and chronic diseases that require blood clotting factors for treatment. Conditions like hemophilia, von Willebrand disease, and thrombophilia necessitate the use of coagulants to manage and control them effectively. The rising incidence of these disorders globally is propelling the demand for this market.
Moreover, technological advancements and the development of novel coagulation therapies are driving innovation and expanding the sector. Manufacturers are investing in research and development to introduce more efficacious and safer products, including recombinant clotting factors and extended half-life products. These advancements aim to enhance patient outcomes, reduce treatment burden, and improve overall quality of life for individuals with bleeding disorders. According to Centers for Disease Control and Prevention, it's estimated that around 33,000 males in the U.S. are living with hemophilia as of May 2024.
Moreover, advancements in medical technology and research have led to development of novel coagulant products with improved efficacy and safety profiles. Innovations like recombinant clotting factors and extended half-life products offer patients more convenient treatment options and better outcomes. These technological advancements drive growth by expanding the range of available therapies and enhancing patient adherence to treatment regimens. In April 2024, Avenacy launched its FDA-approved Desmopressin Acetate Injection in the U.S., serving as a generic alternative to DDAVP Injection. This medication is aimed at treating central diabetes insipidus, hemophilia A, and Type I von Willebrand's disease.
Furthermore, favorable government initiatives and policies aimed at improving healthcare infrastructure and promoting preventive care are boosting the industry. Governments worldwide are focusing on enhancing access to quality healthcare services, including diagnostic testing facilities for early detection and management of disorders such as clotting factor deficiencies and hypercoagulable states. Incentives for research and development activities focused on hemostasis and thrombosis have also encouraged industry players to invest in developing cutting-edge technologies. For instance, initiatives like the National Hemophilia Program are done in collaboration with Centers for Disease Control and Prevention in the U.S. support research efforts to advance hemostasis-related treatments.
Regulatory requirements play a significant role in driving the healthcare industry. With the increasing emphasis on patient safety and quality care, several regulatory bodies including Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented strict guidelines in healthcare settings. These regulations ensure that the products are safe, effective, and of high quality, thereby driving demand for these products. For instance, the FDA has established the Current Good Manufacturing Practice (CGMP) regulations to ensure that they are product under controlled conditions to maintain their identity, strength, quality, and purity. Compliance with these regulations requires manufacturers to invest in advanced technologies and equipment, which in turn drives the demand.
Global Coagulants Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global coagulants market report based on product, application, route of administration, and region.
- Product Outlook (Revenue, USD Million, 2018 - 2030)
- Topical Coagulants
- Absorbable Gelatin
- Oxidized Cellulose
- Microfibrillar Collagen
- Other topical coagulants
- Systemic Coagulants
- Vitamin K
- Protamine
- Desmopressin
- Fibrinogen
- Other systemic coagulants
- Hemostatics
- Application Outlook (Revenue, USD Million, 2018 - 2030)
- Surgeries
- Trauma Cases
- Hemophilia
- Bleeding Disorders
- Other Applications
- Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Topical Administration
- Parenteral Administration
- Oral Administration
- Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Kuwait
- UAE
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Route of Administration
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product and Application outlook
- 2.2.2. Route of Administration outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Coagulants Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Technological advancements in diagnostic tools and treatment options
- 3.2.1.2. Increasing prevalence of coagulants disorders and chronic diseases
- 3.2.1.3. Expanding applications of coagulants testing in various medical fields including hematology, oncology, and critical care
- 3.2.2. Market restraint analysis
- 3.2.2.1. Regulatory Challenges
- 3.3. Coagulants Market Analysis Tools
- 3.3.1. Industry Analysis – Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Pipeline Analysis
- Chapter 4. Coagulants Market: Product Estimates & Trend Analysis
- 4.1. Global Coagulants Market: Product Dashboard
- 4.2. Global Coagulants Market: Product Movement Analysis
- 4.3. Global Coagulants Market by Product, Revenue
- 4.4. Topical Coagulants
- 4.4.1. Topical coagulants market estimates and forecasts 2018 to 2030, (USD Million)
- 4.4.2. Absorbable Gelatin
- 4.4.2.1. Absorbable gelatin market estimates and forecasts 2018 to 2030, (USD Million)
- 4.4.3. Oxidized Cellulose
- 4.4.3.1. Oxidized cellulose market estimates and forecasts 2018 to 2030, (USD Million)
- 4.4.4. Microfibrillar Collagen
- 4.4.4.1. Microfibrillar collagen market estimates and forecasts 2018 to 2030, (USD Million)
- 4.4.5. Other topical coagulants
- 4.4.5.1. Other topical coagulants market estimates and forecasts 2018 to 2030, (USD Million)
- 4.5. Systemic Coagulants
- 4.5.1. Systemic coagulants market estimates and forecasts 2018 to 2030, (USD Million)
- 4.5.2. Vitamin K
- 4.5.2.1. Vitamin K market estimates and forecasts 2018 to 2030, (USD Million)
- 4.5.3. Protamine
- 4.5.3.1. Protamine market estimates and forecasts 2018 to 2030, (USD Million)
- 4.5.4. Desmopressin
- 4.5.4.1. Desmopressin market estimates and forecasts 2018 to 2030, (USD Million)
- 4.5.5. Fibrinogen
- 4.5.5.1. Fibrinogen market estimates and forecasts 2018 to 2030, (USD Million)
- 4.5.6. Other systemic coagulants
- 4.5.6.1. Other systemic coagulants market estimates and forecasts 2018 to 2030, (USD Million)
- 4.6. Hemostatics
- 4.6.1. Hemostatics coagulants market estimates and forecasts 2018 to 2030, (USD Million)
- Chapter 5. Coagulants Market: Application Estimates & Trend Analysis
- 5.1. Global Coagulants Market: Application Dashboard
- 5.2. Global Coagulants Market: Application Movement Analysis
- 5.3. Global Coagulants Market Estimates and Forecasts, By Application, Revenue (USD Million)
- 5.4. Surgeries
- 5.4.1. Surgeries market estimates and forecasts 2018 to 2030, (USD Million)
- 5.5. Trauma Cases
- 5.5.1. Trauma cases market estimates and forecasts 2018 to 2030, (USD Million)
- 5.6. Hemophilia
- 5.6.1. Hemophilia market estimates and forecasts 2018 to 2030, (USD Million)
- 5.7. Bleeding Disorders
- 5.7.1. Bleeding disorders market estimates and forecasts 2018 to 2030, (USD Million)
- 5.8. Other Applications
- 5.8.1. Other applications market estimates and forecasts 2018 to 2030, (USD Million)
- Chapter 6. Coagulants Market: Route of Administration Estimates & Trend Analysis
- 6.1. Global Coagulants Market: Route of Administration Dashboard
- 6.2. Global Coagulants Market: Route of Administration Movement Analysis
- 6.3. Global Coagulants Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
- 6.4. Topical Administration
- 6.4.1. Topical administration market estimates and forecasts 2018 to 2030, (USD Million)
- 6.5. Parenteral Administration
- 6.5.1. Parenteral administration market estimates and forecasts 2018 to 2030, (USD Million)
- 6.6. Oral Administration
- 6.6.1. Oral Administration market estimates and forecasts 2018 to 2030, (USD Million)
- Chapter 7. Coagulants Market: Regional Estimates & Trend Analysis by Product, Application, and Route of Administration
- 7.1. Regional Dashboard
- 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.3. North America
- 7.3.1. U.S.
- 7.3.1.1. Key country dynamics
- 7.3.1.2. Regulatory framework/ reimbursement structure
- 7.3.1.3. Competitive scenario
- 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
- 7.3.2. Canada
- 7.3.2.1. Key country dynamics
- 7.3.2.2. Regulatory framework/ reimbursement structure
- 7.3.2.3. Competitive scenario
- 7.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
- 7.3.3. Mexico
- 7.3.3.1. Key country dynamics
- 7.3.3.2. Regulatory framework/ reimbursement structure
- 7.3.3.3. Competitive scenario
- 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework/ reimbursement structure
- 7.4.1.3. Competitive scenario
- 7.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
- 7.4.2. Germany
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework/ reimbursement structure
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
- 7.4.3. France
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework/ reimbursement structure
- 7.4.3.3. Competitive scenario
- 7.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
- 7.4.4. Italy
- 7.4.4.1. Key country dynamics
- 7.4.4.2. Regulatory framework/ reimbursement structure
- 7.4.4.3. Competitive scenario
- 7.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
- 7.4.5. Spain
- 7.4.5.1. Key country dynamics
- 7.4.5.2. Regulatory framework/ reimbursement structure
- 7.4.5.3. Competitive scenario
- 7.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
- 7.4.6. Norway
- 7.4.6.1. Key country dynamics
- 7.4.6.2. Regulatory framework/ reimbursement structure
- 7.4.6.3. Competitive scenario
- 7.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Key country dynamics
- 7.4.7.2. Regulatory framework/ reimbursement structure
- 7.4.7.3. Competitive scenario
- 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
- 7.4.8. Denmark
- 7.4.8.1. Key country dynamics
- 7.4.8.2. Regulatory framework/ reimbursement structure
- 7.4.8.3. Competitive scenario
- 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.2. China
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.3. India
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive scenario
- 7.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.4. Australia
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework/ reimbursement structure
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.5. South Korea
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework/ reimbursement structure
- 7.5.5.3. Competitive scenario
- 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
- 7.5.6. Thailand
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework/ reimbursement structure
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
- 7.6.2. Argentina
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
- 7.7.3. UAE
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework/ reimbursement structure
- 7.7.3.3. Competitive scenario
- 7.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Regulatory framework/ reimbursement structure
- 7.7.4.3. Competitive scenario
- 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Company/Competition Categorization
- 8.2. Vendor Landscape
- 8.2.1. List of key distributors and channel partners
- 8.2.2. Key customers
- 8.2.3. Key company market share analysis, 2023
- 8.2.4. Johnson & Johnson.
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Baxter International Inc.
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Pfizer Inc.
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Bristol-Myers Squibb Company
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Sanofi S.A.
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Bayer AG
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. Novo Nordisk A/S.
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives
- 8.2.11. CSL Behring
- 8.2.11.1. Company overview
- 8.2.11.2. Financial performance
- 8.2.11.3. Product benchmarking
- 8.2.11.4. Strategic initiatives
- 8.2.12. Octapharma AG
- 8.2.12.1. Company overview
- 8.2.12.2. Financial performance
- 8.2.12.3. Product benchmarking
- 8.2.12.4. Strategic initiatives
- 8.2.13. Grifols S.A.
- 8.2.13.1. Company overview
- 8.2.13.2. Financial performance
- 8.2.13.3. Product benchmarking
- 8.2.13.4. Strategic initiatives
- 8.2.14. Amgen Inc.
- 8.2.14.1. Company overview
- 8.2.14.2. Financial performance
- 8.2.14.3. Product benchmarking
- 8.2.14.4. Strategic initiatives
- 8.2.15. Takeda Pharmaceutical Company Limited
- 8.2.15.1. Company overview
- 8.2.15.2. Financial performance
- 8.2.15.3. Product benchmarking
- 8.2.15.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook